Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy

Fig. 1

Tumor cell characterization in BC subtypes (TNBC, Luminal B, HER2+). EpCAM+ tumor cells were analyzed by flow cytometry. The percentage of CD24+ (A) or CD44+ tumor cells (B) and the CD44/CD24 ratio (C) of mean fluorescence intensities (MFI) are displayed. Graphs represent the proportion of MHC-I (D), MHC-II (E) and PD-L1 (F) among EpCAM+ tumor cells. Each symbol represents a single donor; Data are given as mean ± SD (no significnt differences were detected by Tukey’s multiple comparisons test). Red symbols represent Luminal B breast cancer patients with HER2 over-expression

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us